Growing out of the drag queen ritual of throwing ‘shade ’, or subtly insulting another queen, voguing emerged as a distinctive dance of first the houses and then, inevitably, the balls. ‘It all started at an after hours club called Footsteps on 2nd Avenue and 14th Street ,’. ‘Paris Dupree was there and a bunch of these black queens were throwing shade at each other. Paris had a Vogue magazine in her bag, and while she was dancing she took it out, opened it up to a page where a model was posing and then stopped in that pose on the beat. Then she turned to the next page and stopped in the new pose, again on the beat.’ The provocation was returned in kind. ‘Another queen came up and did another pose in front of Paris, and then Paris went in front of her and did another pose,. ‘This was all shade—they were trying to make a prettier pose than each other—and it soon caught on at the balls. In a way that is what we do at House Of Gummy except instead of 'Voguing' we are buying stocks.\ In this new PART 2 of HOUSE OF GUMMY--- we are going to dial down the hype train. No more cheaply priced stocks that zoom to the moon. This will be a much more stable and IRA focused thread. The amount of stocks profiled will be far less, only the truly good ones will make the cut. First Up- Sarepta Therapeutics- $112
Description Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Michael Chambers recently bought a whopping US $3.7m worth of stock, at a price of US$106. Not only is that a big swing, but it increased their holding size by 19%, Chambers previously made an even bigger purchase of US$6.0m worth of shares at a price of US$105 per share. So it's clear this insider wanted to buy, at around the current price, which is US $112.
Today- Sarepta director buys $1.09M in common stock » 08:43 SRPT Ok it's clear insiders have a thought business is good at Sarepta. Later today lets research the name fully and see if we can include it in a few portfolios.
SRPT Sarepta Therapeutics, Inc. $114.23 +1.82 (+1.62%) Lot of moving parts here- A narrow population FDA target decision back in June caused a 9% sell off- The aim of the Co is to broaden the patient population which is now 6 years old and under. I've read through the CC at earn and it's all very good. I'll highlight parts when I can. Then we will take a TA look and decide if we can purchase now.- Each stock in this thread is going to be followed carefully and kept in portfolio form so there will be many fewer ideas bantered about. I'm still thinking about how balanced it will be etc.
The second quarter of this year was perhaps the most consequential period in the long consequential history of Sarepta. For families living with Duchenne, it was far more than that still. Buddy Cassidy, living with Duchenne and an Elevidys Advisory Committee member, shared the collective view of the Duchenne community on the June approval in words far more eloquent than I could possibly muster. As Buddy said, and I quote, "There is more to do. But now, let us pause and bask in the glow of our achievement. Let us bask in gratitude. Let us pause in celebration. Let us watch as dawn rises and brings in the day." In May of this year, the FDA held an advisory committee meeting on our gene therapy SRP-9001, now called Elevidys. With a majority vote, the advisory committee recommended the approval of Elevidys for the treatment of ambulatory patients with Duchenne muscular dystrophy. On June 22, the FDA granted an accelerated approval for Elevidys to treat Duchenne muscular dystrophy, currently labeled for four- and five-year-old patients. At the time of the approval, FDA leadership informed Sarepta and the patient community that if our confirmatory trial, EMBARK, meets its objectives, the FDA will, in the words of Dr. Peter Marks, move with maximum speed following submission of the data to the agency, minimizing any impediments to review results rapidly, and broadening the label by removing any age restrictions. So we have our path. Our confirmatory trial is well designed and powered to show a statistically significant benefit in the studied population.
Despite being screamingly expensive there is talk of reimbursements: Elevidys is our fourth-approved Duchenne therapy, and we have been very successful with all of our prior launches. Consistent with our track record, the Elevidys launch is going well. A significant number of sites are now initiated and ready to infuse. Payer discussions and negotiations have been more positive than our prior successful therapies, and there is a significant amount of enthusiasm from physicians and families as we have a substantial number of start forms and more coming weekly. In fact, I am pleased to announce that the first reimbursed Elevidys infusion occurred earlier today. Sarepta Therapeutics is a biotech company that develops therapies for rare illnesses, especially Duchenne muscular dystrophy (DMD). This progressive genetic disease is accompanied by several symptoms, most notably muscular weakness. Sarepta Therapeutics has developed four treatments for DMD already, but the latest looks the most promising. In the first quarter, the company's revenue increased by about 20% year over year to $253.5 million, an excellent top-line growth rate for a biotech company. Sarepta Therapeutics estimates peak annual sales of $4 billion for Elevidys, which it co-developed withRoche. The latter owns the rights to Elevidys outside of the U.S. and will pay royalties to Sarepta Therapeutics, which retains the therapy's commercialization right in the U.S. Still, Elevidys should be a meaningful addition to Sarepta Therapeutics' portfolio and help it grow its revenue even faster. But the biotech isn't stopping yet. It is still developing new treatments for DMD and is targeting other rare illnesses as well. The company currently boasts more than 40 programs in its pipeline, which is very impressive for a biotech flirting with large-cap territory at a valuation of nearly $10 billion. Sarepta Therapeutics' innovative potential in rare diseases should yield many more approvals in the coming years, leading to consistently solid financial results and stock market performance for the biotech.
HELLO FOLKS. This is going to be a very tough task. I am going to insist on heavyish insider buying as a prerequisite to any inclusion here in Gummy 2. And these days that kind of company is very hard to find. Welcome To Texas.> https://www.secform4.com/insider-trading/1811074.htm
Why does this stk sell for so much? Texas Pacific Land Corporation (TPL) NYSE - NYSE Delayed Price. 1,848.84 -27.27(-1.45%)<---WTF! At close: 04:00PM EDT
I've discovered an interesting anomaly: " Therapeutics " This is where I am finding the insider buying... I've got another one: